Table 5.

Reported adverse events other than delayed haemolysis in patients treated with a primary regimen of quinine and of patients treated with a primary regimen of artesunate

Primary treatment	Quinine	Artesunate
	n = 31	n = 5
Any adverse event	22 (71%)	3 (60%)
Hypoglycaemia (<50 mg/dl)	10 (32%)	0 (0%)
Hearing disturbances	12 (38%)	0 (0%)
Visual disturbances	1 (3%)	0 (0%)
Hepatotoxicity	1 (3%)*	0 (0%)
Prolongation of the QTc-interval (>500 ms)	3 (10%)	0 (0%)
Acute renal failure	8 (26%)	3 (60%)
Other**	2 (6%)	0 (0%)

* treated with quinine and doxycycline.

*** 1 patient with SIADH, 1 patient with clindamycin-induced eosinophilic pneumonitis.

All p-values for between-group differences >0,05 by Fisher’s exact test.